No Data
No Data
No Data
No Data
No Data
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
Simply Wall StApr 22 08:01 ET
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects With Elevated Lipoprotein(a)
Yahoo FinanceApr 8 11:48 ET
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Yahoo FinanceMar 16 08:29 ET
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 15 11:56 ET
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Yahoo FinanceFeb 16 02:53 ET
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking
Silence Therapeutics plc (NASDAQ:SLN) shares have continued their recent momentum with a 26% gain in the last month alone. Looking back a bit further, it's encouraging to see the stock is up 72% in
Simply Wall StFeb 3 07:00 ET
No Data
No Data